NCT06659341View on ClinicalTrials.gov

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

PHASE1RecruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

November 8, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

March 7, 2028

Conditions
Advanced Solid Tumors Harboring KRAS G12C Mutation
Interventions
DRUG

BAY3498264

Oral

Trial Locations (10)

2100

RECRUITING

Rigshospitalet - Kræftbehandling, Copenhagen OE

2109

RECRUITING

Macquarie University Hospital - Oncology Department, Macquarie Park

2640

RECRUITING

Border Medical oncology - Albury Wodonga Regional Cancer Centre, Albury

3199

RECRUITING

Peninsula and Southeast Oncology, Frankston

8907

RECRUITING

Institut Catala D'oncologia - Hematologia, L'Hospitalet de Llobregat

20089

RECRUITING

Gruppo Humanitas - Humanitas Research Hospital - Cancer Center, Rozzano

00168

RECRUITING

Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica, Rome

08035

NOT_YET_RECRUITING

Hospital Universitari Vall d'Hebron- Oncology Service, Barcelona

SM2 5PT

RECRUITING

The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH) - Sutton, Sutton

M20 4BX

RECRUITING

The Christie NHS Foundation Trust - Christie Hospital, Manchester

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT06659341 - A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation | Biotech Hunter | Biotech Hunter